Article: 3M Health Care's Aldara receives EMA approval.(Brief Article)

3M Health Care says that the European Medicines Agency has cleared its topical response modifier Aldara (imiquimod) cream 5% for the treatment of superficial basal cell carcinoma in adults, marking the first such agent to be approved for this condition. The approval was based on the results from two double-blind, randomized, vehicle-controlled clinical trials involving 364 patients with a single BCC, treated with Aldara or placebo five times a week for six weeks. ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!